Gujarat Themis Biosyn will convene an Extraordinary General Meeting (EGM) on Saturday, August 22, 2026, to secure shareholder approval for significant related party transactions. The company proposes borrowing up to ₹450 crore and obtaining guarantees worth up to ₹1,000 crore from promoter group entities to fund strategic acquisitions, subsidiary investments, and working capital augmentation. This move provides the company with financial flexibility to execute its growth strategy without sole reliance on external financing.

The proposed transactions involve Dr. Sachin D. Patel, Managing Director and Promoter, along with Pharmaceutical Business Group India Limited (PBGIL) and Themis Medicare Limited (TML). Under the Companies Act, 2013, and SEBI Listing Regulations, these transactions qualify as material related party transactions due to their scale relative to the company’s turnover. The Audit Committee and the Board of Directors have reviewed and approved the terms, which include commercially reasonable interest rates benchmarked against prevailing market rates for similar borrowings. The borrowings are unsecured, though security may be mutually agreed upon.

Key Transaction Details

In addition to the funding approvals, shareholders will vote on a special resolution to amend Article 13(1)(c) of the Articles of Association. The amendment removes the mandatory requirement for a registered valuer’s report for all further issues of share capital, aligning the company’s internal governance with the current statutory framework under the Companies Act, 2013 and SEBI regulations. This change aims to streamline future equity issuances where valuation reports are not legally mandated.

Debt Securities Authorization

The EGM will also consider a special resolution authorizing the private placement of Non-Convertible Debentures (NCDs) and other debt securities. The Board seeks an enabling resolution to issue debt instruments with an outstanding principal amount not exceeding ₹1,500 crore. This authorization allows the company to diversify its debt portfolio and access competitive borrowing sources through private placements to eligible investors, including mutual funds, banks, and institutional buyers. The Board retains discretion to determine terms, pricing, and listing arrangements based on prevailing market conditions.

What the Numbers Show

The scale of the proposed related party transactions is significant relative to the company’s recent financial performance. The proposed borrowing of ₹450 crore represents approximately 271% of the listed entity’s annual standalone turnover for the preceding financial year. Similarly, the proposed guarantee of ₹1,000 crore equates to 603% of that turnover. For context, PBGIL reported a standalone turnover of ₹2.57 crore in FY25, while TML reported ₹342.24 crore. The heavy reliance on promoter group funding underscores the company’s aggressive expansion phase, particularly in strategic acquisitions, which may not yet be fully supported by internal cash flows or traditional banking channels. Shareholders should note that existing borrowings from these entities were nil in FY25, indicating this is a new line of credit rather than a renewal.

Voting and Logistics

Remote e-voting will be available from August 19, 2026, at 9:00 am to August 21, 2026, at 5:00 pm, via the Central Depository Services Limited (CDSL) platform. The cut-off date for voting eligibility is Saturday, August 15, 2026. Shareholders holding shares as on this date can cast their votes electronically. Physical attendance is also permitted at the Vapi venue for those who have not voted remotely. The scrutinizer for the process is Mr. Ketan R. Shirwadkar of M/s. KRS AND CO., Practicing Company Secretaries.

Vividhmargi Investments Private Limited (VIPL), a promoter group entity, has created an indirect encumbrance over Gujarat Themis Biosyn Limited shares through a pledge and non-disposal undertaking on its stake in Pharmaceutical Business Group (India) Limited (PBGIL). The disclosure, filed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reveals that VIPL has pledged 25,24,245 equity shares in PBGIL, constituting 51% of its issued and paid-up share capital. Since PBGIL holds 47.02% of Gujarat Themis Biosyn, this move creates a significant indirect lien on the listed company’s promoter holdings.

The encumbrance was created in favor of CTL Trusteeship Limited, acting as the debenture trustee for OSS Software Solutions Labs Private Limited. A Pledge Agreement cum Non-Disposal Undertaking dated June 28, 2026, formalized the security interest, with the pledge taking effect from June 29, 2026. Additionally, VIPL provided a non-disposal undertaking over another 21,57,855 equity shares in PBGIL, representing 47.988% of its capital. This structure ensures that nearly the entire stake held by VIPL in PBGIL is now subject to restrictions or security interests.

Structure of Indirect Encumbrance

The chain of ownership linking the pledge to Gujarat Themis Biosyn is direct. VIPL holds 49,49,500 equity shares in PBGIL, which constitutes 98.988% of PBGIL’s issued and paid-up share capital. PBGIL, in turn, holds 5,12,40,000 equity shares in Gujarat Themis Biosyn, accounting for 47.02% of the listed company’s total diluted share and voting capital. Consequently, the pledge over VIPL’s majority stake in PBGIL translates into an indirect encumbrance on the substantial block held by PBGIL in the listed entity.

The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited on July 1, 2026, by Deesha Srikkanth, Senior Vice President at CTL Trusteeship Limited. The filing clarifies that no direct acquisition of shares in Gujarat Themis Biosyn has occurred; rather, the regulatory requirement stems from the creation of encumbrances over the intermediate holding company. The total equity share capital of Gujarat Themis Biosyn remains unchanged at INR 10,89,65,265, comprising 10,89,65,265 fully paid-up equity shares of INR 1/- each.

What the Numbers Show

The pledge covers exactly 51% of PBGIL’s share capital, while the non-disposal undertaking covers the remaining 47.988%, leaving only a negligible fraction of VIPL’s stake in PBGIL unencumbered. This near-total restriction on VIPL’s ability to dispose of its PBGIL shares suggests that the financing arrangement secured by OSS Software Solutions Labs Private Limited is heavily collateralized against the promoter group’s strategic holding. For investors in Gujarat Themis Biosyn, this indicates that the promoter group’s liquidity needs are being met by leveraging their control stake in the listed company, albeit indirectly.